Clinical Trials Logo

Mental Disorders clinical trials

View clinical trials related to Mental Disorders.

Filter by:

NCT ID: NCT00070889 Completed - Psychoses Clinical Trials

Brain Cell Injury in Patients With A First Episode of Psychosis

Start date: September 1999
Phase: N/A
Study type: Observational

Patients experiencing a first episode of psychosis may have brain cell damage due to a chemical process called oxidation. This study will compare patients with psychosis to healthy volunteers to determine if there are differences in their blood that reflect oxidative brain cell damage.

NCT ID: NCT00070876 Completed - Clinical trials for Mental Disorders Diagnosed in Childhood

Psychosocial Training for Pediatric Health Care Providers

Start date: August 2002
Phase: N/A
Study type: Interventional

This study will provide psychosocial training to general health care providers to help them provide better care to children with mental health problems.

NCT ID: NCT00057161 Completed - Mental Illness Clinical Trials

Homelessness Prevention: Psychiatric Care With Representative Payeeship

Start date: n/a
Phase: N/A
Study type: Interventional

Money management is a neglected issue in maintaining persons with mental illness in the community. This randomized controlled trial (RCT) assessed whether a community-based representative payee program, i.e., money management of Social Security and/or VA benefits, coordinated with VA psychiatric care (CO-RP) could be more effective than customary treatment for veterans who had no representative payee.

NCT ID: NCT00056472 Completed - Clinical trials for Major Depressive Disorder With Psychotic Features

Study of Pharmacotherapy of Psychotic Depression

STOP-PD
Start date: January 2003
Phase: Phase 3
Study type: Interventional

This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.

NCT ID: NCT00044187 Completed - Schizophrenia Clinical Trials

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Start date: April 2001
Phase: Phase 4
Study type: Interventional

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

NCT ID: NCT00035802 Completed - Bipolar Disorder Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder

Start date: January 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.

NCT ID: NCT00034892 Completed - Schizophrenia Clinical Trials

CAFE Comparison of Atypicals in First Episode of Psychosis

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

NCT ID: NCT00034775 Completed - Schizophrenia Clinical Trials

A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

Start date: August 2001
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.

NCT ID: NCT00034762 Completed - Alzheimer Disease Clinical Trials

Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease

Start date: December 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease

NCT ID: NCT00024908 Completed - Healthy Clinical Trials

Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex

Start date: October 1, 2001
Phase: N/A
Study type: Observational

This study will examine the underlying mental processes that determine how people understand social behavior, remember information, and think. Language, planning, problem solving, reasoning, social behavior, and memory are the critical parts of cognition that make up daily life. This study will explore the association between performance on various experimental tasks and day-to-day functioning. Healthy normal volunteers and patients with certain kinds of brain damage (primarily focal or degenerative lesions of the human prefrontal cortex) or psychiatric disorders may be eligible for this study. Candidates with central nervous system trauma, disease or dysfunction will be screened with a routine neurological examination and history. Participants may be asked to complete written tests, sit in front of a computer monitor and press a key to indicate a decision about what appears on the screen (for example, whether a statement is accurate) and answer questions from a test examiner. A skin conductance response (SCR) test may be done along with some of the cognitive tests. SCR uses electrodes (pieces of metal attached to wires) placed on the fingers to measure the subject's emotional reaction to a test. Participants may also do an evoked response test, in which the subject watches words or scenes on a TV screen while his or her responses are recorded from electrodes placed on the scalp (similar to an electroencephalogram). The tests will be scheduled for an average of one session a week, with each session lasting from 30 minutes to 3 hours. Generally, 15 sessions will be scheduled over a 1-year period. Special arrangements will be made to accommodate participants from out-of-town. Participants may have a magnetic resonance imaging (MRI) scan of the brain. This test uses radio waves and a strong magnetic field to picture structural and chemical changes in tissue. For the procedure, the subject lies on a table in a space enclosed by a metal cylinder (the scanner) for about 1 hour. In addition, some study subjects will be invited to participate in a training study designed to improve their planning or social behavior. Participation requires coming to NIH daily over a 1- to 2-month period for 1 to 2 hours each visit.